Molecular targeting of hypoxia in radiotherapy

被引：150
作者：
Rey, Sergio [1 ,2 ]
Schito, Luana [1 ,2 ]
Koritzinsky, Marianne [1 ,2 ,3 ]
Wouters, Bradly G. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto Med Discovery Tower,101 Coll St,Rm 12-310, Toronto, ON M5G 1L7, Canada
[2] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON, Canada
[3] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[4] Univ Toronto, Med Biophys, Toronto, ON, Canada
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2017年 / 109卷
关键词：
Cancer Metabolism; Hypoxia Tolerance; Hypoxia; HIF; Ionizing Radiation; Radiosensitizers; ROS; Targeted Cancer Therapy; Tumor Microenvironment; UPR; Drug Delivery; ENDOTHELIAL GROWTH-FACTOR; CANCER STEM-CELLS; INDUCIBLE FACTOR 1-ALPHA; MESSENGER-RNA TRANSLATION; MITOCHONDRIAL COMPLEX-III; INCREASES TUMOR RADIOSENSITIVITY; POSITRON-EMISSION-TOMOGRAPHY; PREDICTS RADIATION RESPONSE; INDUCED CHROMOSOMAL DAMAGE; UNFOLDED PROTEIN RESPONSE;
D O I：
10.1016/j.addr.2016.10.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Hypoxia (low O-2) is an essential microenvironmental driver of phenotypic diversity in human solid cancers. Hypoxic cancer cells hijack evolutionarily conserved, O-2- sensitive pathways eliciting molecular adaptations that impact responses to radiotherapy, tumor recurrence and patient survival. In this review, we summarize the radiobiological, genetic, epigenetic and metabolic mechanisms orchestrating oncogenic responses to hypoxia. In addition, we outline emerging hypoxia- targeting strategies that hold promise for individualized cancer therapy in the context of radiotherapy and drug delivery. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码：45 / 62
页数：18
相关论文
共 386 条
[1]  
Aebersold DM, 2001, CANCER RES, V61, P2911
[2]   Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator [J].
Ahn, G-One ;
Botting, K. Jane ;
Patterson, Adam V. ;
Ware, David C. ;
Tercel, Moana ;
Wilson, William R. .
BIOCHEMICAL PHARMACOLOGY, 2006, 71 (12) :1683-1694
[3]   Optimization of the auxiliary ligand shell of cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs [J].
Ahn, GO ;
Ware, DC ;
Denny, WA ;
Wilson, WR .
RADIATION RESEARCH, 2004, 162 (03) :315-325
[4]  
Airley RE, 2005, INT J ONCOL, V26, P1477
[5]   Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells [J].
Al-Assar, Osama ;
Demiciorglu, Fevzi ;
Lunardi, Serena ;
Gaspar-Carvalho, Maria Manuela ;
McKenna, William Gillies ;
Muschel, Ruth M. ;
Brunner, Thomas B. .
RADIOTHERAPY AND ONCOLOGY, 2014, 111 (02) :243-251
[6]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[7]   Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study [J].
Albertella, Mark R. ;
Loadman, Paul M. ;
Jones, Philip H. ;
Phillips, Roger M. ;
Rarnpling, Roy ;
Burnet, Neil ;
Alcock, Chris ;
Anthoney, Alan ;
Vjaters, Egils ;
Dunk, Chris R. ;
Harris, Peter A. ;
Wong, Alvin ;
Lalani, Alshad S. ;
Twelves, Chris J. .
CLINICAL CANCER RESEARCH, 2008, 14 (04) :1096-1104
[8]   LKB1-dependent signaling pathways [J].
Alessi, Dario R. ;
Sakamoto, Kei ;
Bayascas, Jose R. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :137-163
[9]   18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models [J].
Ali, Rehan ;
Apte, Sandeep ;
Vilalta, Marta ;
Subbarayan, Murugesan ;
Miao, Zheng ;
Chin, Frederick T. ;
Graves, Edward E. .
PLOS ONE, 2015, 10 (10)
[10]   PYRUVATE AND RELATED ALPHA-KETOACIDS PROTECT MAMMALIAN-CELLS IN CULTURE AGAINST HYDROGEN PEROXIDE-INDUCED CYTO-TOXICITY [J].
ANDRAE, U ;
SINGH, J ;
ZIEGLERSKYLAKAKIS, K .
TOXICOLOGY LETTERS, 1985, 28 (2-3) :93-98
12345678910